Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websitebrooksidecapital.com
Phone415.233.4640
Emailjtrea@brooksideca...
Employees

Funds

Offices

San Francisco, USA
2269 Chestnut Street, #400
San Francisco, CA, 94123
USA

People

President
Director of Client Services
Board of Advisors
Board of Advisors
Board of Advisors
Board of Advisors
Board of Advisors
Board of Advisors
Show All People

Tags

Brookside Capital

They design, implement, and manage custom tailored portfolios of liquid assets for high net worth investors. In order to avoid the potential conflict of interest found in most of the financial industry, they do not accept commissions on any transactions in client accounts. They sell no assets. Instead, they charge a management fee that is based on the market value of the account. That fee ranges from 1.5% per year down to 0.5%, depending on the size of the account.

For the safety of the client’s assets, they do not hold cash or securities at Brookside Capital, Inc. Assets are held at a brokerage firm or bank custodian of the client’s choice. The minimum account size is generally $1 million.

There is a wide range of issues to consider when designing a portfolio strategy for a client. Among these issues are age, other assets held, income requirements, taxes, specific funding goals, and personal preferences. However, the most important consideration is defining the acceptable level of risk for each client. They have found that this is both a financial and comfort level that varies broadly by client. Through financial modeling and some proprietary questionnaires, they help the client understand their specific acceptable risk level, and then design a strategy that optimizes the potential rate of return without exceeding that risk limit.

Stated simply, all clients want to make as much money as they can—without exceeding their own unique risk level.

In selecting assets, they start the decision process at what they call the “SEP” level. SEP stands for “Social, Economic, and Political” themes. Their research has unquestionably shown that understanding these global, long-term themes is the most essential element in determining investment success or failure. Their Board of Advisors is the key group in helping them understanding these themes. Some examples include The Revolution in Healthcare, Homeland Security, Consumer Value, The Information Age: Part 3, Nanometrics, and The Education Failure. There are many others, and the list is fluid and always evolving.

They meet with their clients often to keep them up to date on their portfolios and their outlook. This also gives them the opportunity to keep their current on any changes in their lives so that they can make any necessary adjustments in their portfolio strategy.

Recent Milestones

Investments

Company Date Round Size Participants
NJOY 2/2014Private Equity$70M3
Zafgen 12/2013Series E$45M4
Dicerna Pharmaceuticals 7/2013Series C$60M9
Radius Health 4/2013Private Equity$43M6
PTC Therapeutics 3/2013Private Equity$60M8
Radius Health 12/2011Private Equity$21.4M7
Radius Health 7/2011Series C$66M7
Brightcove 4/2010Series D$12M7
Youku 12/2009Series E$40M4
Thumbplay 3/2009Series F$8M6
Youku 6/2008Series D$40M5
Concert Pharmaceuticals 4/2008Series C$37M12
Thumbplay 3/2008Series E$18M2
Virtual Iron Software 11/2007Series D$13M6
Youku 11/2007Series C$25M4
MAP Pharmaceuticals 3/2007Series D$50M6
diaDexus 1/2007Series E$40M7
Brightcove 1/2007Series C$59.5M11
Concert Pharmaceuticals 11/2006Series B$48.5M8
Tengion 6/2006Series B$50M7
MetaSolv 5/2005Venture Round$21.9M7
Perlegen Sciences 2/2005Series D$74M15
FibroGen 2/2005Private Equity$100M13

Videos

Sources

  1. E-Cig Maker NJOY Raises $70 Million (techcrunch.com) [edit]
  2. Zafgen Secures $45M in Series E Equity Financing (finsmes.com) [edit]
  3. Dicerna Pharmaceuticals Raises $60M In Series C Financing (finsmes.com) [edit]
  4. Radius Health Completes $43 Million Financing to Advance BA058 for the Treatment of Osteoporosis (finance.yahoo.com) [edit]
  5. PTC Therapeutics Completes $60M Financing (finsmes.com) [edit]
  6. Radius Health pulls in $21.4M more for Phase III bone drug (fiercebiotech.com) [edit]
  7. Radius Health, Inc.: Series C $66M (onbiovc.com) [edit]
  8. Brightcove Raises Another $12 Million; Says An IPO May Come Next Year (paidcontent.org) [edit]
  9. Chinese YouTube Youku Raises $40 Million Round (businessinsider.com) [edit]
  10. SEC (sec.gov) [edit]
  11. Chinese Video Site Youku Raises $40 Million Fourth Round (paidcontent.org) [edit]
  12. Capital Funding Report [edit]
  13. Thumbplay raises $18 million for wireless entertainment (venturebeat.com) [edit]
  14. Virtual Iron gets $13 million in new financial round, outlines new strategy (virtualization.info) [edit]
  15. Youku.com Raises US$25M Series C Round (jlmpacificepoch.com) [edit]
  16. MAP Pharma raises $50M for respiratory and CNS disease treatments (venturebeat.com) [edit]
  17. DiaDexus Raises $40M Series E For Expansion (scalevp.com) [edit]
  18. Brightcove Raises Another $59.5 Million In Third Round; NYTCO Among New Investors (paidcontent.org) [edit]
  19. Concert Pharmaceuticals Raises $48.5 Million in Series B Financing (concertpharma.com) [edit]
  20. Tengion Inc. Completes $50 Million Series "B" Round Financing led by Bain Capital and Quaker BioVentures will support neo-bladder clinical trials, manufacturing capacity and pipeline development (tengion.com) [edit]
  21. EDGAR [edit]
  22. Perlegen Raises $74 Million to Apply Pharmacogenomics to Late-Stage Drug Pipeline. (allbusiness.com) [edit]
  23. FIBROGEN COMPLETES EQUITY FINANCING (fibrogen.com) [edit]
Edit This Page
Last Edited 3/2/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy